BABurça Aydın

Burça Aydın

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Burça Aydın has a total of 175 co-authors. Here are the top co-authors by number of shared publications:

  • Ali Varan

    Department of Pediatric Oncology, Hacettepe University Cancer Institute, Ankara, Turkey

    17 shared publications
  • Münevver Büyükpamukçu

    Department of Pediatric Oncology, Hacettepe University Cancer Institute, Ankara, Turkey

    16 shared publications
  • Canan Akyüz

    Department of Pediatric Oncology, Hacettepe University Cancer Institute, Ankara, Turkey

    14 shared publications
  • Bilgehan Yalçın

    Department of Pediatric Oncology, Institute of Cancer, Hacettepe University Faculty of Medicine, Ankara, Turkey

    11 shared publications
  • Canan Akyuz

    Department of Pediatric Oncology, Hacettepe University Cancer Institute, Ankara, Turkey

    11 shared publications
  • Tezer Kutluk

    Department of Pediatric Oncology, Hacettepe University Cancer Institute, Ankara, Turkey

    11 shared publications

Latest Publications

  • Open Access

    Cross-Sectional Comparison of Nutritional Risk Screening and Assessment Tools in Pediatric Oncology Patients

    by Şeniz Öztürk, Güzide Burça Aydın, Murat Baş

    Background/Objectives: No nutritional assessment method is accepted as a gold standard in pediatric oncology. We translated and culturally adapted Pediatric PG-SGA and SCAN into Turkish and evaluated content validity, 24-h test–retest reliability, and agreement with STRONGkids, anthropometry, and an AND/ASPEN-based definition of moderate-to-severe malnutrition; this is not a complete validation of all measurement properties. Methods: Cross-sectional study of 163 children aged 2 to <15 years with lymphoma or solid tumors, assessed at diagnosis or during the first three chemotherapy cycles. All instruments were completed within one encounter by the same unblinded dietitian; STRONGkids served as a comparator, not a gold standard. Results: Content validity was high for both instruments. Scores correlated strongly with STRONGkids (Spearman’s rho 0.919, 95% CI 0.885–0.943, and 0.852, 95% CI 0.794–0.895), but shared item content and a single data source mean these coefficients reflect that overlap rather than independent convergent validity. Relative test–retest reliability was high (ICC 0.994 and 0.980), although Pediatric PG-SGA scores rose significantly at retest and its smallest detectable change (1.91 points) exceeded the interval between the thresholds examined. At the externally validated SCAN cutoff of ≥3, agreement with STRONGkids was moderate (kappa 0.516); the higher kappa at ≥5 (0.877) reflects a threshold tuned to that comparator. Agreement with the AND/ASPEN definition was fair to moderate (kappa 0.176–0.447). Conclusions: Both instruments demonstrated content validity and high relative test–retest reliability and are usable for screening, but a positive screen is not a diagnosis of malnutrition, and no outcome benefit was evaluated. The exploratory ≥ 5 and ≥8 thresholds require confirmation in an independent population.

  • Solid Malignant Tumors in Infancy

    by Öykü D. Kanbur, Nilgün Kurucu, Hilal Susam Şen, G. Burça Aydin, Bilgehan Yalçın, Ali Varan, Tezer Kutluk

    Infantile tumors are rare and different from those in older children in terms of anatomic site, histologic features, and behavior. Thus, they require adapted multimodality approaches for diagnosis and treatment. We aimed to evaluate the characteristics and outcomes of different tumor types in children under 1 year of age who were referred to the Hacettepe University Pediatric Oncology Department over 20 years. There were 515 infants, with a mean age of 6.1±3.4 months, diagnosed with malignant tumors. The male/female ratio was 1.15. Thirty-three (6.4%) of them were diagnosed in the newborn period. Prenatal diagnosis was made in 4.9% of the patients. The most common finding was a mass and symptoms related to the mass (81.6%). The mean time to diagnosis was 31.3±44.7 days. The most common histopathologic diagnoses were retinoblastomas (33.6%), neuroblastomas (27.1%), renal tumors (10.3%), and central nervous system (CNS) tumors (9.7%). Forty patients (7.8%) had congenital anomalies, genetic syndromes and diseases, and metabolic and immune deficiency disorders. Multimodal treatment was administered according to diagnosis, stage, and risk group. The 5-year overall survival (OS) was 86.6% in the whole group and 83.4% in newborns. The best 5-year OS (>91.5%) was observed for renal tumors, retinoblastomas, and neuroblastomas. Conversely, the lowest OS was observed for CNS tumors (52.5%). Our results contribute to a better understanding of the characteristics and outcomes of the tumors in this age group.

  • Open Access

    Assessment of factors affecting timing of discharge in pediatric cancer patients with febrile neutropenia

    by Ceren Üstün, Burça Aydın, Nilgün Kurucu, Bilgehan Yalçın, Ali Varan, Tezer Kutluk

    Background. Febrile neutropenia is a common cause of hospital admissions among pediatric cancer patients. To optimize personalized approaches for hospitalization and antibiotic treatment, risk stratification has been proposed. This study aimed to explore the impact of clinical and laboratory parameters on risk stratification for patient discharge. Methods. This prospective study included pediatric lymphoma and solid tumor patients who were hospitalized due to febrile neutropenia between June 2018 and June 2019. Patient characteristics, primary oncological diagnosis and disease status, comorbid conditions, time elapsed after the last course of chemotherapy, use of granulocyte-colony stimulating factor (G-CSF) prophylaxis, presence of port catheter, infection type, fever values/duration, physical examination findings, and duration of neutropenia were collected. Laboratory investigations including complete blood counts, acute phase reactants at the onset of the episode, culture results were also recorded. Results. The study examined 142 febrile neutropenic episodes from 88 consecutive patients. The median age of the study group was 6.8 years, with 19.3% of cases being lymphoma and 80.7% having solid tumors. The median hospital stay was 7 days. Factors associated with longer hospitalization periods included a lymphoma diagnosis, presence of comorbid conditions, bone marrow involvement, and febrile neutropenic period during hospitalization. Patients presenting with fever ≥ 39 °C at admission, poor general appearance, hypotension, prolonged capillary filling time, and severe infection signs had longer hospital stays. In febrile neutropenic episodes, absolute monocyte count ≤ 100 cells/mm3, platelet count ≤ 50,000/mm3, and prolonged neutropenia delayed discharge time. Patients with microbiologically defined infections, especially those with positive catheter cultures, also had delayed discharge. Conclusion. The diagnosis of lymphoma, poor general condition at admission, presence of microbiologically defined infection, thrombocytopenia, delayed recovery of absolute neutrophil counts, and prolonged fever duration were significant factors in determining the treatment duration and predicting discharge time.

  • Open Access

    Re-irradiation in progressive diffuse infiltrative pontine glioma in children and young adults

    by Alper Kahvecioglu, Mustafa Cengiz, Guzide Burca Aydin, Mustafa Tezer Kutluk, Gokcen Coban Cifci, Gozde Yazici

    Purpose: This study aims to assess oncological outcomes in children and young adults with diffuse infiltrative pontine glioma (DIPG) who have progressed after initial radiotherapy (RT), with an emphasis on the role of re-irradiation. Methods: Data from 33 patients aged 25 years or younger with progressive disease after initial RT were retrospectively analyzed. Results: The median age at diagnosis was 8 years (range 4–24 years), and the median initial RT dose was 54 Gy (range 39–54 Gy). The median time between initial RT and progression was 8 months (range 3–40 months). In addition to systemic therapy, 15 patients (46%) received re-irradiation due to progression, with a median dose of 23.4 Gy (range 19.8–36 Gy), while 18 patients (54%) were treated with systemic therapy alone. In patients who received re-irradiation after progression, the 1‑year post-progression overall survival (OS) was significantly higher compared to those treated with systemic therapy alone (27% vs. 0%, p = 0.01). Among the 15 re-irradiated patients, 9 out of 12 with available data (75%) showed improvement in neurological symptoms following re-irradiation. No patient exhibited acute or late RT-related ≥ grade 3 toxicity. Conclusion: Palliative re-irradiation in children and young adults with progressive DIPG after initial RT provides an approximately 3‑month OS benefit and clinical improvement without significant toxicity and should be considered as a standard-of-care approach.


  • Pulmonary involvement in children with Langerhans cell histiocytosis

    by Çağrı Coşkun, Tezer Kutluk, Bilgehan Yalçın, Berna Oğuz, Diclehan Orhan, Ebru Yalçın, Eren Müngen, İnCi Yaman Bajin, Uğur Özçelik, Burça Aydın, et al.

    Background. Pulmonary Langerhans cell histiocytosis (pLCH) is a rare disease, mostly a component of multisystemic LCH. We aimed to investigate the clinical features and treatment results in children with pLCH. Methods. We retrospectively reviewed the clinical, radiological, and treatment data of 37 patients with pLCH, diagnosed from 1974 to 2022. Results. 10% (n=37) of 367 patients with LCH had lung involvement. The median age was 1.8 years (range: 0.4 & 17.7) with a male-to-female ratio of 2.3. At admission 29.7% (n=11) presented with respiratory symptoms. Imaging showed a spectrum from nodular opacities to multiple cysts. All but one patient had multisystem disease. Twenty-nine received vinblastine-containing therapy. Ten-year event-free (EFS) and overall survival (OS) rates were 47.8% and 63.3%, respectively. In children younger and older than two years of age, the 10-year EFS was 53.3% vs. 40.2% and the 10-year OS was 58.7% vs. 68.8%, respectively. In children with and without risk organ involvement, 10-year EFS was 51.9% vs. 46.3% and 10-year OS was 51.9% vs. 73.7%. Conclusions. Lung and multisystem involvement are significant concerns in LCH, highlighting the need for careful management to reduce morbidity and mortality.


  • PEDIATRIC LOW GRADE LYMPHOMAS: A REPORT FROM A SINGLE CENTRE

    by N. Kurucu, T. Kutluk, A. Sağlam, B. Oğuz, M. Haliloğlu, B. Aydın, B. Yalçın, A. Varan, A. Üner

  • Ifosfamide-induced Encephalopathy With Rapid Response to Thiamine: A Pediatric Case

    by Eren Müngen, İnCi Yaman Bajin, Sibel Öz, Ceren Günbey, Banu Anlar, Burca Aydin

    Ifosfamide is an important chemotherapeutic agent used in the therapeutic protocols of many malignant tumors. Central nervous system toxicity of ifosfamide manifests with encephalopathy in 10% to 30% of patients treated with ifosfamide. Thiamine and methylene blue have been reported beneficial in the treatment and prevention of ifosfamide-induced encephalopathy (IIE). We describe an episode of encephalopathy developed at the third cycle of ifosfamide treatment in a child with Ewing sarcoma. With the administration of thiamin, the encephalopathy resolved and no episode was noted during subsequent courses of ifosfamide. Previous use of cisplatin, concomitant use of opioids, low levels of serum albumin and hemoglobin, and elevated levels of serum creatinine are potential risk factors for IIE. The current case illustrates the possibility of IIE even in the absence of such additional risk factors, treated successfully with thiamin and draws attention to the need for close neurological monitorization of patients treated with ifosfamide.


  • Open Access

    Bilateral Wilms tumors: Treatment results from a single center

    by Burça Aydın, Münevver Büyükpamukçu, Nilgün Kurucu, Ali Varan, Ferah Yıldız, Zuhal Akçören, Berna Oğuz, Saniye Ekinci, Bilgehan Yalçın, Canan Akyüz, et al.

    The management of bilateral Wilms tumor (BWT) is challenging, particularly due to its presentation at a younger age, rarity, and difficulty for treatment decisions and surgical evaluation comparing to unilateral WT. In this study, the outcome of BWT patients from a single center who were treated by the Turkish Pediatric Oncology Group (TPOG) Wilms Tumor Regimen were retrospectively reviewed. From 1990 to 2016, 30 patients with synchronous BWT were treated with a preoperative chemotherapy of vincristine and actinomycin-D (VA). Chemotherapy was continued until safe nephron sparing surgery (NSS) could be performed for as long as radiological tumor response continued; otherwise, the chemotherapy was intensified by adding doxorubicin (D) alternating with VA every 6 weeks. The median followup of patients was 59 months (4-297 months). The median duration of preoperative chemotherapy was 81 days and ranged between 14 days and 198 days. Preoperative chemotherapy was modified in seven patients (23%) to the VAD regimen. Twenty-two patients (73%) had a radical nephrectomy on the larger tumor and NSS on the contralateral kidney, and 6 patients (20%) had bilateral NSS. Postoperative tumor stages for stage I, II and III were 60%, 22% and 14%, respectively. The 5-year event free survival (EFS) rates were 100%, 90% and 51% for stages I, II and III (p=0.02), respectively. Unfavorable histology and nephrogenic rests were reported in 20% and 20% of patients, respectively. The 5-year overall survival (OS) and EFS rates were 50% and 25%, respectively, in patients with anaplasia, while the same rates were 96% and 96% in patients with favorable histology tumors (p=0.05 and p < 0.001). The 10-year EFS and OS rates for all patients were 82% and 86%, respectively. Our results are comparable with the literature. VA is effective as initial preoperative treatment of BWT and allows for safe resection.


  • FAB LMB 96 Regimen for Newly Diagnosed Burkitt Lymphoma in Children: Single-center Experience

    by Burca Aydin, Canan Akyuz, Neslihan Kalkan, Nilgun Kurucu, Ali Varan, Bilgehan Yalcin, Tezer Kutluk

    Background/Objectives: The outcome of Burkitt lymphoma has improved by over 90%. In this study, demographic characteristics and outcomes of 57 patients with Burkitt lymphoma treated with FAB LMB 96 regimen are presented. Materials and Methods: Standard intensity arms were selected for all risk groups. Clinical characteristics, response to treatment, and outcome were evaluated. Results: The median age of 48 boys and 9 girls was 8.2 years. There were 2 (3%), 41 (72%), and 14 (25%) patients in the low, intermediate, and high-risk groups, respectively. Patients were followed-up for a median of 50 months. The 5-year overall survival and event-free survival rates for the study group were 90.8% and 87.4%, respectively. Two patients in the low-risk group are still alive without evidence of disease for 17 and 57 months. The 5-year overall survival rates were 95% and 78% for intermediate and high-risk patients, and the 5-year event-free survival rates were 93% and 62%, respectively. At the end of induction, 58% of patients had complete response, and 42% (n=24) had residual tumors. A total of 16 of 24 patient biopsies showed no viable tumors. Conclusions: Our results confirm the previously published survival results of FAB LMB 96. The regimen is an effective regimen for mature B-cell non-Hodgkin lymphoma without radiotherapy or surgery even in central nervous system–positive patients. The most important prognostic factor is the complete response after induction chemotherapy. However, residual tumor at the end of consolidation might not always be a sign for unresponsive tumor. Tumoral residue should be radiologically well evaluated and biopsied if possible for viability before intensifying treatment.


  • ICE Regimen for Relapsed/Refractory Bone and Soft Tissue Sarcomas in Children

    by Burca Aydin, Canan Akyuz, Ali Varan, Bilgehan Yalcin, Nilgun Kurucu, Tezer Kutluk

    Background: The outcome of bone and soft tissue sarcomas (BST) after relapse has very poor prognosis with survival rates less than 39%. Unfortunately there are not many treatment options, but promising responses have been reported with ifosfamide, etoposide and carboplatin (ICE). Objective: Therefore, we planned a study for children with recurrent/refractory BST treated with ICE regimen to evaluate their demographic features, responses to treatment and outcome. Method: Patients with primary diagnosis of BST and treated with ICE regimen at the time of first or subsequent relapse, progression or unresponsive disease were selected for study. The files were retrospectively evaluated. Results: Thirty of sixty-six patients had metastatic disease at relapse. Patients received median 5 cycles of ICE and were followed-up median 16.3 months. Overall survival rates were 83% and 62% at 1st and 2nd year. The ORR to the regimen was 43%. Survival rates were significantly higher in good responders (3-year EFS and OS rates: 50% vs. 8% and 78% vs. 14%; p<0.0001 and p<0.0001). Survival rates for non-metastatic disease were 42% and 75% for EFS and OS and higher than patients with metastases at relapse (p<0.001 and p<0.0001). EFS and OS rates of patients with rhabdomyosarcoma were 42% and 69%. No grade 3 or 4 renal toxicity was documented. Conclusion: ICE combination improves the outcome of relapsed or refractory sarcomas and it might serve as second line treatment. Patients with no metastases at relapse would benefit more than others with metastatic disease.